Sign in or create an account to add this stock to your watchlist.
About Abiomed (NASDAQ:ABMD)
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. It also manufactures and sells AB5000 circulatory support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, the company engages in the research, development, prototyping, and the pre-serial production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart with an external drive shaft. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio5.84
Quick Ratio5.24
Price-To-Earnings
Trailing P/E Ratio157.69
Forward P/E Ratio112.64
P/E Growth4.09
Sales & Book Value
Annual Sales$593.75 million
Price / Sales28.81
Cash Flow$1.3648 per share
Price / Cash283.09
Book Value$15.57 per share
Price / Book24.81
Profitability
EPS (Most Recent Fiscal Year)$2.45
Net Income$112.17 million
Net Margins18.89%
Return on Equity17.58%
Return on Assets15.37%
Miscellaneous
Employees908
Outstanding Shares44,280,000
Abiomed (NASDAQ:ABMD) Frequently Asked Questions
What is Abiomed's stock symbol?
Abiomed trades on the NASDAQ under the ticker symbol "ABMD."
How were Abiomed's earnings last quarter?
Abiomed (NASDAQ:ABMD) announced its earnings results on Thursday, May, 3rd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.16. The medical equipment provider earned $174.44 million during the quarter, compared to analysts' expectations of $164.30 million. Abiomed had a return on equity of 17.58% and a net margin of 18.89%. The business's revenue was up 39.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.33 EPS. View Abiomed's Earnings History.
When is Abiomed's next earnings date?
What price target have analysts set for ABMD?
9 analysts have issued 12-month target prices for Abiomed's shares. Their forecasts range from $280.00 to $370.00. On average, they expect Abiomed's share price to reach $323.1429 in the next twelve months. View Analyst Ratings for Abiomed.
Who are some of Abiomed's key competitors?
Some companies that are related to Abiomed include Stryker (SYK), Becton Dickinson (BDX), Fresenius (FSNUY), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Cantel Medical (CMD), Insulet (PODD), Globus Medical (GMED) and Haemonetics (HAE).
Who are Abiomed's key executives?
Abiomed's management team includes the folowing people:
- Mr. Michael R. Minogue, Chairman, Chief Exec. Officer and Pres (Age 51)
- Dr. David M. Weber Ph.D., Chief Operating Officer (Age 57)
- Mr. Michael G. Howley, VP & GM of Global Sales (Age 54)
- Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 66)
- Mr. Todd A. Trapp, CFO & VP (Age 47)
Has Abiomed been receiving favorable news coverage?
News stories about ABMD stock have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Abiomed earned a media sentiment score of 0.15 on Accern's scale. They also gave news coverage about the medical equipment provider an impact score of 47.31 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Abiomed's major shareholders?
Abiomed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include
PRIMECAP MANAGEMENT COMPANY
(9.23%),
PRIMECAP MANAGEMENT COMPANY
(9.23%), BlackRock Inc. (8.35%), Baillie Gifford & Co. (4.62%), Palo Alto Investors LP (3.04%) and Winslow Capital Management LLC (1.77%). Company insiders that own Abiomed stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for Abiomed.
Which major investors are selling Abiomed stock?
ABMD stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Millennium Management LLC, American Century Companies Inc., Wells Fargo & Company MN, Sei Investments Co., Scout Investments Inc., Blair William & Co. IL and OppenheimerFunds Inc.. Company insiders that have sold Abiomed company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Paul Thomas and William J Bolt. View Insider Buying and Selling for Abiomed.
Which major investors are buying Abiomed stock?
ABMD stock was purchased by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Franklin Resources Inc., BlackRock Inc., JPMorgan Chase & Co., Rockefeller Capital Management L.P., Prudential Financial Inc., Baillie Gifford & Co. and FIL Ltd. View Insider Buying and Selling for Abiomed.
How do I buy shares of Abiomed?
Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abiomed's stock price today?
One share of ABMD stock can currently be purchased for approximately $386.35.
How big of a company is Abiomed?
Abiomed has a market capitalization of $16.79 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. Abiomed employs 908 workers across the globe.
How can I contact Abiomed?
Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]
MarketBeat Community Rating for Abiomed (ABMD)
MarketBeat's community ratings are surveys of what our community members think about Abiomed and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Abiomed (NASDAQ:ABMD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Abiomed in the last 12 months. Their average twelve-month price target is $323.1429, suggesting that the stock has a possible downside of 16.36%. The high price target for ABMD is $370.00 and the low price target for ABMD is $280.00. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.78 | 2.78 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $323.1429 | $305.8571 | $301.50 | $180.4286 |
| Price Target Upside: | 16.36% downside | 9.99% upside | 12.61% upside | 6.47% downside |
Abiomed (NASDAQ:ABMD) Consensus Price Target History
Abiomed (NASDAQ:ABMD) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Abiomed (NASDAQ:ABMD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Abiomed (NASDAQ ABMD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 87.79%
Abiomed (NASDAQ ABMD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/8/2018 | Martin P Sutter | Director | Sell | 21,890 | $343.50 | $7,519,215.00 | 46,668 |  |
| 5/7/2018 | Michael G Howley | VP | Sell | 17,500 | $348.11 | $6,091,925.00 | 64,257 | |
| 5/7/2018 | William J Bolt | SVP | Sell | 22,790 | $348.03 | $7,931,603.70 | 66,414 | |
| 2/20/2018 | Andrew J Greenfield | VP | Sell | 20,000 | $270.36 | $5,407,200.00 | | |
| 10/30/2017 | Dorothy E Puhy | Director | Sell | 6,364 | $179.08 | $1,139,665.12 | 39,532 | |
| 10/30/2017 | Michael G Howley | VP | Sell | 10,000 | $178.64 | $1,786,400.00 | 56,757 | |
| 10/2/2017 | Andrew J Greenfield | VP | Sell | 11,282 | $169.32 | $1,910,268.24 | | |
| 8/30/2017 | Eric A Md Rose | Director | Sell | 982 | $145.17 | $142,556.94 | 13,634 | |
| 8/24/2017 | Eric A Md Rose | Director | Sell | 23,018 | $151.09 | $3,477,789.62 | 24,652 | |
| 8/15/2017 | Paul Thomas | Director | Sell | 10,000 | $154.71 | $1,547,100.00 | 12,172 | |
| 7/31/2017 | David M Weber | COO | Sell | 16,500 | $147.63 | $2,435,895.00 | 125,122 | |
| 5/16/2017 | Michael G Howley | VP | Sell | 18,279 | $133.56 | $2,441,343.24 | 62,105 | |
| 5/8/2017 | David M Weber | COO | Sell | 21,250 | $130.89 | $2,781,412.50 | 123,771 | |
| 5/8/2017 | Dorothy E Puhy | Director | Sell | 13,500 | $131.12 | $1,770,120.00 | 38,249 | |
| 5/8/2017 | Michael G Howley | VP | Sell | 600 | $132.84 | $79,704.00 | 48,305 | |
| 3/17/2017 | Andrew J Greenfield | VP | Sell | 10,000 | $124.00 | $1,240,000.00 | 66,307 | |
| 12/13/2016 | Dorothy E Puhy | Director | Sell | 8,000 | $120.00 | $960,000.00 | 32,749 | |
| 11/30/2016 | Eric A Md Rose | Director | Sell | 8,000 | $110.81 | $886,480.00 | 21,259 | |
| 9/22/2016 | Michael R Minogue | CEO | Sell | 28,039 | $127.07 | $3,562,915.73 | 215,488 | |
| 9/21/2016 | Michael R Minogue | CEO | Sell | 5,034 | $127.07 | $639,670.38 | 215,782 | |
| 9/19/2016 | Michael R Minogue | CEO | Sell | 58,710 | $127.00 | $7,456,170.00 | 215,782 | |
| 8/15/2016 | Dorothy E Puhy | Director | Sell | 5,160 | $123.94 | $639,530.40 | 24,749 | |
| 8/10/2016 | Dorothy E Puhy | Director | Sell | 3,900 | $122.31 | $477,009.00 | 33,811 | |
| 8/8/2016 | Michael G Howley | VP | Sell | 17,853 | $119.20 | $2,128,077.60 | 65,558 | |
| 8/1/2016 | Henri A Termeer | Director | Sell | 25,866 | $118.70 | $3,070,294.20 | 325,778 | |
| 6/29/2016 | Michael G Howley | VP | Sell | 10,000 | $106.58 | $1,065,800.00 | 65,558 | |
| 6/7/2016 | Andrew J Greenfield | VP | Sell | 9,000 | $104.16 | $937,440.00 | 65,234 | |
| 5/23/2016 | David M Weber | COO | Sell | 4,342 | $96.97 | $421,043.74 | 100,159 | |
| 5/16/2016 | David M Weber | COO | Sell | 5,604 | $94.56 | $529,914.24 | 116,783 | |
| 5/6/2016 | David M Weber | COO | Sell | 2,145 | $93.82 | $201,243.90 | 117,411 | |
| 5/5/2016 | David M Weber | COO | Sell | 52,000 | $95.27 | $4,954,040.00 | 121,676 | |
| 5/5/2016 | Paul Thomas | Director | Sell | 7,500 | $95.14 | $713,550.00 | 28,811 | |
| 4/18/2016 | Andrew J Greenfield | VP | Sell | 10,000 | $99.10 | $991,000.00 | 61,186 | |
| 4/13/2016 | Michael G Howley | VP | Sell | 9,800 | $98.64 | $966,672.00 | 62,268 | |
| 4/8/2016 | Michael G Howley | VP | Sell | 200 | $98.80 | $19,760.00 | 52,668 | |
| 4/1/2016 | Dorothy E Puhy | Director | Sell | 10,000 | $95.02 | $950,200.00 | 47,792 | |
| 3/31/2016 | Andrew J Greenfield | VP | Sell | 15,000 | $94.11 | $1,411,650.00 | 58,941 | |
| 3/24/2016 | David M Weber | COO | Sell | 5,235 | $89.93 | $470,783.55 | 113,411 | |
| 3/22/2016 | Andrew J Greenfield | VP | Sell | 24,800 | $89.06 | $2,208,688.00 | 73,614 | |
| 3/22/2016 | Dorothy E Puhy | Director | Sell | 10,000 | $90.30 | $903,000.00 | 52,190 | |
| 3/21/2016 | Andrew J Greenfield | VP | Sell | 19,572 | $89.07 | $1,743,278.04 | 73,614 | |
| 3/10/2016 | Andrew J Greenfield | VP | Sell | 200 | $89.00 | $17,800.00 | 54,242 | |
| 3/8/2016 | David M Weber | COO | Sell | 17,521 | $85.20 | $1,492,789.20 | 125,761 | |
| 3/8/2016 | William J Bolt | SVP | Sell | 17,510 | $85.19 | $1,491,676.90 | 98,392 | |
| 3/7/2016 | David M Weber | COO | Sell | 8,111 | $85.21 | $691,138.31 | 125,761 | |
| 3/7/2016 | Dorothy E Puhy | Director | Sell | 4,000 | $85.00 | $340,000.00 | 66,190 | |
| 3/7/2016 | William J Bolt | SVP | Sell | 7,987 | $85.20 | $680,492.40 | 98,392 | |
| 2/8/2016 | Dorothy E. Puhy | Director | Sell | 4,000 | $80.47 | $321,880.00 | 62,190 | |
| 8/19/2015 | Michael R. Minogue | CEO | Sell | 146,800 | $104.87 | $15,394,916.00 | 239,718 | |
| 8/17/2015 | Dorothy E Puhy | Director | Sell | 2,580 | $103.91 | $268,087.80 | | |
| 8/14/2015 | Dorothy E Puhy | Director | Sell | 2,580 | $105.27 | $271,596.60 | | |
| 7/17/2015 | Michael G Howley | VP | Sell | 21,295 | $70.00 | $1,490,650.00 | | |
| 6/15/2015 | Andrew J Greenfield | VP | Sell | 3,185 | $65.00 | $207,025.00 | | |
| 5/29/2015 | Martin P Sutter | Director | Buy | 7,500 | $60.17 | $451,275.00 | | |
| 5/27/2015 | David M Weber | COO | Sell | 17,968 | $60.77 | $1,091,915.36 | | |
| 5/12/2015 | Michael G Howley | VP | Sell | 17,353 | $66.47 | $1,153,453.91 | | |
| 5/7/2015 | Andrew J Greenfield | VP | Sell | 3,500 | $71.00 | $248,500.00 | | |
| 5/7/2015 | Robert Bowen | CFO | Sell | 2,372 | $71.52 | $169,645.44 | | |
| 5/6/2015 | David M Weber | COO | Sell | 1,605 | $73.72 | $118,320.60 | | |
| 5/6/2015 | Michael R Minogue | CEO | Sell | 8,840 | $73.12 | $646,380.80 | | |
| 5/6/2015 | William J Bolt | SVP | Sell | 1,750 | $74.27 | $129,972.50 | | |
| 3/23/2015 | David M Weber | COO | Sell | 3,765 | $71.08 | $267,616.20 | | |
| 10/31/2014 | Andrew J Greenfield | VP | Sell | 15,000 | $31.90 | $478,500.00 | | |
| 10/31/2014 | Michael R Minogue | CEO | Sell | 164,000 | $31.14 | $5,106,960.00 | | |
| 7/28/2014 | Michael R Minogue | CEO | Sell | 82,383 | $26.30 | $2,166,672.90 | | |
| 5/27/2014 | Andrew J Greenfield | VP | Sell | 7,026 | $21.10 | $148,248.60 | | |
| 5/27/2014 | David M Weber | COO | Sell | 10,172 | $21.11 | $214,730.92 | | |
| 5/27/2014 | Michael R Minogue | CEO | Sell | 90,001 | $21.19 | $1,907,121.19 | | |
| 5/27/2014 | Robert Bowen | CFO | Sell | 6,820 | $21.11 | $143,970.20 | | |
| 5/27/2014 | William J Bolt | SVP | Sell | 8,029 | $21.10 | $169,411.90 | | |
| 5/15/2014 | David Weber | COO | Sell | 1,425 | $20.94 | $29,839.50 | 130,482 | |
| 5/15/2014 | Michael Howley | VP | Sell | 1,267 | $20.94 | $26,530.98 | 74,486 | |
| 5/15/2014 | Michael Minogue | CEO | Sell | 4,433 | $20.94 | $92,827.02 | 260,912 | |
| 5/15/2014 | William Bolt | SVP | Sell | 1,110 | $20.94 | $23,243.40 | 94,205 | |
| 1/10/2014 | Robert Bowen | CFO | Sell | 37,500 | $30.00 | $1,125,000.00 | 66,929 | |
| 9/3/2013 | David Weber | COO | Sell | 6,500 | $24.00 | $156,000.00 | 126,907 | |
| 9/3/2013 | William Bolt | SVP | Sell | 20,000 | $24.00 | $480,000.00 | 89,718 | |
| 8/14/2013 | William Bolt | SVP | Sell | 21,534 | $23.35 | $502,818.90 | 89,718 | |
| 8/13/2013 | David Weber | COO | Sell | 4,400 | $23.00 | $101,200.00 | 133,407 | |
| 8/13/2013 | Michael Howley | VP | Sell | 8,400 | $23.00 | $193,200.00 | 68,753 | |
| 8/5/2013 | David Weber | COO | Sell | 7,100 | $22.90 | $162,590.00 | 137,807 | |
| 8/5/2013 | Michael Howley | VP | Sell | 1,600 | $23.03 | $36,848.00 | 77,153 | |
| 8/5/2013 | Robert Bowen | CFO | Sell | 2,235 | $22.64 | $50,600.40 | 66,929 | |
| 8/5/2013 | W Gerald Austen | Director | Sell | 8,000 | $22.85 | $182,800.00 | | |
| 8/5/2013 | William Bolt | SVP | Sell | 20,166 | $22.70 | $457,768.20 | 98,552 | |
| 7/31/2013 | Michael R Minogue | CEO | Sell | 36,500 | $25.04 | $913,960.00 | | |
| 7/17/2013 | Michael G Howley | VP | Sell | 10,000 | $24.45 | $244,500.00 | | |
| 7/15/2013 | Robert Bowen | CFO | Sell | 40,786 | $23.50 | $958,471.00 | | |
| 7/11/2013 | Robert Bowen | CFO | Sell | 1,499 | $23.50 | $35,226.50 | | |
| 6/4/2013 | David M Weber | COO | Sell | 6,519 | $21.20 | $138,202.80 | | |
| 6/4/2013 | Michael G Howley | VP | Sell | 3,881 | $21.20 | $82,277.20 | | |
| 6/4/2013 | Michael R Minogue | CEO | Sell | 17,667 | $21.23 | $375,070.41 | | |
| 6/4/2013 | Robert Bowen | CFO | Sell | 5,298 | $21.20 | $112,317.60 | | |
| 6/4/2013 | William J Bolt | SVP | Sell | 4,967 | $21.20 | $105,300.40 | | |
| 5/29/2013 | Michael R Minogue | CEO | Sell | 58,833 | $21.83 | $1,284,324.39 | | |
| 5/28/2013 | David M Weber | COO | Sell | 6,018 | $22.18 | $133,479.24 | | |
| 5/28/2013 | Michael G Howley | VP | Sell | 5,476 | $22.18 | $121,457.68 | | |
| 5/28/2013 | Robert Bowen | CFO | Sell | 5,102 | $22.18 | $113,162.36 | | |
| 5/28/2013 | William J Bolt | SVP | Sell | 4,629 | $22.18 | $102,671.22 | | |
| 5/23/2013 | Andrew J Greenfield | VP | Sell | 1,666 | $21.63 | $36,035.58 | | |
| 5/23/2013 | Michael R Minogue | CEO | Sell | 5,666 | $21.62 | $122,498.92 | | |
| 5/17/2013 | Robert Bowen | CFO | Sell | 2,715 | $23.50 | $63,802.50 | | |
| 5/9/2013 | Michael R Minogue | CEO | Sell | 20,000 | $21.00 | $420,000.00 | | |
| 5/7/2013 | Henri A Termeer | Director | Buy | 100,000 | $19.86 | $1,986,000.00 | | |
| 2/25/2013 | Henri A Termeer | Director | Buy | 100,000 | $14.98 | $1,498,000.00 | | |
(Data available from 1/1/2013 forward)
Abiomed (NASDAQ ABMD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Allscripts Acquires HealthGrid to Improve Patient Outcome
finance.yahoo.com - May 22 at 4:16 PM |
| Ecolab (ECL) Rolls Out HDI for Improved Food Surveillance
finance.yahoo.com - May 22 at 4:16 PM |
| Analyzing ABMD, BR, and TFX Stocks
finance.yahoo.com - May 21 at 4:16 PM |
 | Abiomed (ABMD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 20 at 8:14 AM |
 | Why ABIOMED (ABMD) Could Be an Impressive Growth Stock
www.nasdaq.com - May 18 at 10:59 AM |
| Zacks: Brokerages Anticipate Abiomed (ABMD) Will Announce Quarterly Sales of $171.90 Million
www.americanbankingnews.com - May 18 at 2:00 AM |
 | Top Buys In Healthcare & IT Following Q1 EPS Exceeding Estimates And Continuing Into Q2
www.forbes.com - May 17 at 4:14 PM |
| Thermo Fisher (TMO) Gains on Latest Buyouts Despite Cost Woes
finance.yahoo.com - May 17 at 4:14 PM |
 | Veeva Rolls Out Nitro to Unify Healthcare Industry Data
www.zacks.com - May 17 at 9:53 AM |
| $0.80 EPS Expected for Abiomed (ABMD) This Quarter
www.americanbankingnews.com - May 16 at 9:16 PM |
 | Form 4 ABIOMED INC For: May 07 Filed by: Howley Michael G
www.streetinsider.com - May 10 at 4:18 PM |
| Here's Why You Should Invest in Intuitive Surgical Right Now
finance.yahoo.com - May 10 at 4:18 PM |
| Form 4 ABIOMED INC For: May 08 Filed by: SUTTER MARTIN P
www.streetinsider.com - May 10 at 9:55 AM |
| Form 4 ABIOMED INC For: May 07 Filed by: PUHY DOROTHY E
www.streetinsider.com - May 10 at 9:55 AM |
| Insider Selling: Abiomed (ABMD) Director Sells 21,890 Shares of Stock
www.americanbankingnews.com - May 9 at 10:14 PM |
| Abiomed (ABMD) SVP Sells $7,931,603.70 in Stock
www.americanbankingnews.com - May 9 at 10:14 PM |
| Michael G. Howley Sells 17,500 Shares of Abiomed (ABMD) Stock
www.americanbankingnews.com - May 9 at 10:14 PM |
| Is ABIOMED (ABMD) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - May 9 at 4:19 PM |
| ABIOMED (ABMD) Earnings Beat Estimates in Q4, View Impressive
finance.yahoo.com - May 7 at 4:19 PM |
| Abiomed to Post Q2 2019 Earnings of $0.67 Per Share, William Blair Forecasts (ABMD)
www.americanbankingnews.com - May 7 at 4:38 AM |
| Q1 2019 EPS Estimates for Abiomed Lifted by Leerink Swann (ABMD)
www.americanbankingnews.com - May 7 at 4:38 AM |
| Q1 2019 Earnings Estimate for Abiomed (ABMD) Issued By Piper Jaffray
www.americanbankingnews.com - May 7 at 4:38 AM |
| Abiomed's Revenue Growth Accelerates to 40%
finance.yahoo.com - May 4 at 4:19 PM |
 | Abiomed's Revenue Growth Accelerates to 40%
www.fool.com - May 4 at 10:46 AM |
| Today’s Research Reports on Stocks to Watch: Cardinal Health and ABIOMED
finance.yahoo.com - May 4 at 9:32 AM |
| Edited Transcript of ABMD earnings conference call or presentation 3-May-18 12:00pm GMT
finance.yahoo.com - May 4 at 9:32 AM |
| Abiomed (ABMD) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - May 3 at 11:50 PM |
| Abiomed (ABMD) Upgraded by ValuEngine to "Strong-Buy"
www.americanbankingnews.com - May 3 at 11:47 PM |
| Abiomed (ABMD) Price Target Increased to $360.00 by Analysts at Piper Jaffray
www.americanbankingnews.com - May 3 at 10:04 PM |
| Why Abiomed Stock Is Flying High Today
finance.yahoo.com - May 3 at 4:16 PM |
| Abiomed (ABMD) Posts Earnings Results, Beats Expectations By $0.24 EPS
www.americanbankingnews.com - May 3 at 3:16 PM |
 | Abiomed Announces Q4 FY 2018 Revenue of $174 Million
www.lse.co.uk - May 3 at 9:36 AM |
 | Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33 ...
globenewswire.com - May 3 at 9:36 AM |
 | BRIEF-Abiomed Reports Q4 GAAP Earnings Per Share $0.80
www.reuters.com - May 3 at 9:36 AM |
| Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33%, Over Prior Year
finance.yahoo.com - May 3 at 9:36 AM |
| Abiomed: Fiscal 4Q Earnings Snapshot
finance.yahoo.com - May 3 at 9:36 AM |
 | Abiomed Earnings Outlook
www.benzinga.com - May 2 at 4:17 PM |
| Abiomed (ABMD) Price Target Raised to $320.00
www.americanbankingnews.com - May 1 at 2:38 PM |
| Research Report Identifies Altair Engineering, Safety Insurance Group, Tyler Technologies, Veracyte, Enviva Partners ...
globenewswire.com - May 1 at 9:40 AM |
| $163.84 Million in Sales Expected for Abiomed (ABMD) This Quarter
www.americanbankingnews.com - May 1 at 3:50 AM |
| Analysts Expect Abiomed (ABMD) Will Post Earnings of $0.64 Per Share
www.americanbankingnews.com - April 29 at 9:21 AM |
| Zacks Investment Research Downgrades Abiomed (ABMD) to Hold
www.americanbankingnews.com - April 25 at 12:14 PM |
| Abiomed (ABMD) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 25 at 8:50 AM |
| Abiomed (ABMD) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 25 at 2:02 AM |
| Abiomed (ABMD) Given a $145.00 Price Target by Piper Jaffray Analysts
www.americanbankingnews.com - April 19 at 11:52 PM |
| Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?
finance.yahoo.com - April 17 at 9:52 AM |
| Abiomed (ABMD) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - April 16 at 12:02 PM |
| Abiomed (ABMD) Expected to Announce Quarterly Sales of $163.84 Million
www.americanbankingnews.com - April 14 at 4:17 AM |
 | Artificial Organs Global Market Forecast to 2023 - Market Projected to Reach $21 Billion Growing at a CAGR of 9.5%
www.prnewswire.com - April 13 at 10:04 AM |
| Abiomed Fourth Quarter Fiscal 2018 Earnings and Conference Call Notification
finance.yahoo.com - April 13 at 10:04 AM |
Abiomed (NASDAQ:ABMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Abiomed (NASDAQ:ABMD) Income Statement, Balance Sheet and Cash Flow Statement
Abiomed (NASDAQ ABMD) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
